<DOC>
	<DOCNO>NCT00684463</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety single IV dose Onicit® ( Palonosetron ) 0.25 mg prevention acute delay nausea vomit associate moderate highly emetogenic chemotherapy .</brief_summary>
	<brief_title>Palonosetron Moderately Highly Emetogenic Chemotherapy Induced Nausea Vomiting ( Study P04935 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Patients must 18 year age old . Histological cytological confirmation malignant disease . Karnofsky index &gt; = 50 % Naïve chemotherapy ( First Cycle chemotherapy IV moderate high emetic risk administer Day 1 study , accord modification classification Paul Hesketh 's schema publish Annals Oncology 17 : 2028 , 2006 ( Appendix 3 ) . Patients voluntarily sign consent form . Pregnancy suspect . Patients breast feed . Inability understand cooperate study procedure . Received investigational drug within 30 day study entry . Received drug potential antiemetic efficacy within 24 hour prior begin treatment Seizure disorder require anticonvulsant medication . Persistent vomit due organic etiology . Experienced vomiting , nausea retching , 24 hour prior chemotherapy . Any systemic disease different base disease Known current history drug alcohol abuse Gastric outlet intestinal obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Antiemetic</keyword>
</DOC>